1 study found for:    NCT01191060
Show Display Options
Rank Status Study
1 Active, not recruiting Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Conditions: Multiple Myeloma;   Patients Aged up to 65 Years;   Progression Free Survival Prolongation;   Disease Progression;   Overall Survival
Intervention: Drug: Lenalidomide, Bortézomib

Indicates status has not been verified in more than two years